

## Supplementary Data

**Figure S1. Polymorphic residues.** (A) The HLA-B\*35:08 molecule is represented in green cartoon, with HLA-B\*35:01 in orange cartoon. The unique polymorphic residue at position 156 is represented in stick. (B) The graphic represents the surface of the HLA-B\*35:08 molecule in white, with the LPEP peptide in cyan. The polymorphic residues are coloured in pink; A41, N80, R82, G83 and W167 in the HLA-B\*35:08 molecule, correspond to T41, T80, L82, R83 and S167 in the HLA-B\*44:02 molecule.

**Figure S2. Analysis of SB27, CA5 and SB47 TCR binding to HLA-B35:08<sup>LPEP</sup> and HLA-B\*35:01<sup>LPEP</sup>.** The left and middle panels show the binding curves of immobilized SB27 (A), CA5 (B) and SB47 (C) TCRs with serial dilutions of HLA-B35:08<sup>LPEP</sup> and HLA-B\*35:01<sup>LPEP</sup> in the fluid phase, respectively. The right panels show kinetic fits for the binding of SB27 (A), CA5 (B) and SB47 (C) TCRs with serial dilutions of HLA-B\*35:08<sup>LPEP</sup>.

**Figure S3. Unbiased and refined density around the LPEP peptide.** Unbiased (A and C) and refined (B and D) electron densities for the CA5 (A and B) and SB47 (C and D) ternary complexes. The unbiased electron density maps were generated via mFo-Fc maps at 3 sigma (green); refined density maps are contoured at 1 sigma with 2Fo-DFc maps (blue). The peptide is represented in black stick format.

**Figure S4. Structural comparison of the SB47 TCR-pMHC-I complex.** The N-terminally focused docking topology of the SB47 TCR (A) was structurally similar to the MHC-II-restricted autoimmune 3A6 TCR (B), the OB.1A12 TCR (C), and the E8 TCR (D). All MHC antigen binding clefts are coloured in white cartoon, with peptides shown as black sticks. CDR1 $\alpha$ , purple; CDR2 $\alpha$ , green; CDR3 $\alpha$ , red; CDR1 $\beta$  yellow; CDR2 $\beta$ , sand; CDR3 $\beta$ , orange.

**Table S1. Thermal stability assays of HLA B\*35:08 mutants bound to the LPEP peptide.**

**Table S2. Surface plasmon resonance experiments for HLA-B\*35:08<sup>LPEP</sup> mutants and the SB27 and SB47 TCRs.**

**Table S3. Contact table for the CA5 TCR with the HLA-B\*35:08<sup>LPEP</sup> complex.**

**Table S4. Contact table for the SB47 TCR with the HLA-B\*35:08<sup>LPEP</sup> complex.**

**Table S1. Thermal stability assays of HLA B\*35:08 mutants bound to the LPEP peptide.**

<b>HLA B*35:08 mutant-LPEP</b>	<b>T<sub>m</sub> (°C)</b>
B*35:08 wild-type-LPEP	60.3 ± 1.0
B*35:08-E55A-LPEP	57.3 ± 1.0
B*35:08-D61A-LPEP	59.0 ± 1.7
B*35:08-R62A-LPEP	59.8 ± 1.0
B*35:08-I66A-LPEP	48.5 ± 0.4
B*35:08-L163A-LPEP	57.0 ± 0.6
B*35:08-E166A-LPEP	57.6 ± 1.6
B*35:08-R170A-LPEP	57.1 ± 1.4

T<sub>m</sub>, or thermal melt, is the temperature required to reach 50% unfolded protein.

**Table S2. Surface plasmon resonance experiments for HLA-B\*35:08<sup>LPEP</sup> mutants and the SB27 and SB47 TCRs.**

<b>HLA-B*35:08 mutant-LPEP</b>	<b>SB27 TCR Kd<sub>eq</sub> (μM)</b>	<b>SB47 TCR Kd<sub>eq</sub> (μM)</b>
B*35:08 wild-type-LPEP	10.4 ± 1.6	22.3 ± 1.6
B*35:08-E55A-LPEP	12.6 ± 0.6	NB
B*35:08-D61A-LPEP	11.7 ± 0.1	NB
B*35:08-R62A-LPEP	17.5 ± 7.3	NB
B*35:08-I66A-LPEP	60.8 ± 10.0	160.6 ± 24.7
B*35:08-R151A-LPEP	87.1 ± 6.2	28.9 ± 2.4
B*35:08-Q155A-LPEP	48.1 ± 5.6	25.7 ± 0.7
B*35:08-L163A-LPEP	16.1 ± 3.4	>200
B*35:08-E166A-LPEP	18.5 ± 0.5	162 ± 5.7
B*35:08-R170A-LPEP	5.4 ± 0.4	NB

Equilibrium dissociation constants (Kd<sub>eq</sub>) were determined from duplicate measurements for SB27 and SB47 TCR binding to HLA-B\*35:08 wild-type and mutants bound to the LPEP peptide. The Kd<sub>eq</sub> values represent the mean ± standard error of the mean (sem).

**Table S3. Contact table for the CA5 TCR with the HLA-B\*35:08<sup>LPEP</sup> complex.**

TCR gene segment	CA5 TCR	HLA-B*35:08	Type of bond
CDR1 $\alpha$	Thr <sup>36</sup>	Ala <sup>158</sup> , Gly <sup>162</sup>	VDW
CDR1 $\alpha$	Thr <sup>36</sup> O- $\gamma$ 1	Ala <sup>158</sup> O	H-bond
CDR2 $\alpha$	Asn <sup>57</sup>	Glu <sup>154</sup>	VDW
CDR2 $\alpha$	Asn <sup>57</sup> N- $\delta$ 2	Glu <sup>154</sup> O- $\epsilon$ 1	H-bond
CDR2 $\alpha$	Phe <sup>59</sup>	Glu <sup>154</sup> , Arg <sup>157</sup> , Ala <sup>158</sup> , Glu <sup>161</sup>	VDW
CDR3 $\alpha$ -N	Phe <sup>110</sup>	Gln <sup>155</sup> , Ala <sup>158</sup> ,	VDW
CDR3 $\alpha$ -N	Phe <sup>110</sup> O	Gln <sup>155</sup> N- $\epsilon$ 2	H-bond
CDR3 $\alpha$ -J	Tyr <sup>111</sup>	Gln <sup>155</sup> , Ala <sup>158</sup> , Tyr <sup>159</sup> , Leu <sup>163</sup>	VDW
CDR3 $\beta$ -N	Glu <sup>109</sup>	Ala <sup>150</sup> , Arg <sup>151</sup>	VDW
CDR3 $\beta$ -J	Thr <sup>110</sup>	Arg <sup>151</sup>	VDW
TCR gene segment	CA5 TCR	LPEP peptide	Type of bond
CDR1 $\alpha$	Tyr <sup>38</sup>	Gln <sup>7</sup>	VDW
CDR1 $\alpha$	Tyr <sup>38</sup> OH	Gln <sup>7</sup> N $\epsilon$ 1	H-bond
CDR3 $\alpha$ -V	Ser <sup>108</sup>	Gln <sup>7</sup>	VDW
CDR3 $\alpha$ -V	Ser <sup>108</sup> O- $\gamma$	Gln <sup>7</sup> N- $\epsilon$ 2	H-bond
CDR3 $\alpha$ -N	Gly <sup>109</sup>	Gln <sup>7</sup>	VDW
CDR3 $\alpha$ -N	Phe <sup>110</sup>	Pro <sup>6</sup> , Gln <sup>7</sup>	VDW
CDR3 $\alpha$ -J	Tyr <sup>111</sup>	Pro <sup>4</sup> , Leu <sup>5</sup> , Gln <sup>7</sup>	VDW
CDR3 $\alpha$ -J	Asn <sup>112</sup>	Leu <sup>5</sup> , Pro <sup>6</sup> , Gln <sup>7</sup>	VDW
CDR3 $\alpha$ -J	Asn <sup>112</sup> N	Leu <sup>5</sup> O	H-bond
CDR3 $\alpha$ -J	Asp <sup>114</sup>	Gln <sup>7</sup>	VDW
CDR1 $\beta$	Met <sup>27</sup>	Gln <sup>9</sup>	VDW
CDR1 $\beta$	Asn <sup>28</sup>	Gln <sup>9</sup>	VDW
CDR1 $\beta$	Asn <sup>28</sup> N- $\delta$ 2	Gln <sup>9</sup> N- $\epsilon$ 2	H-bond
CDR1 $\beta$	His <sup>29</sup>	Gln <sup>7</sup> , Gly <sup>8</sup> , Gln <sup>9</sup>	VDW
CDR1 $\beta$	Asn <sup>37</sup>	Pro <sup>6</sup> , Gln <sup>7</sup> , Gly <sup>8</sup>	VDW
CDR1 $\beta$	Asn <sup>37</sup> N	Gln <sup>7</sup> O, Gly <sup>8</sup> O	H-bond
CDR1 $\beta$	Asn <sup>37</sup> N- $\delta$ 2	Pro <sup>6</sup> O, Gly <sup>8</sup> O	H-bond
CDR1 $\beta$	Ser <sup>38</sup>	Gln <sup>7</sup>	VDW
CDR1 $\beta$	Ser <sup>38</sup> N	Gly <sup>7</sup> O	H-bond
FW $\beta$	Tyr <sup>40</sup>	Gln <sup>7</sup>	VDW
FW $\beta$	Tyr <sup>40</sup> OH	Gln <sup>7</sup> N- $\epsilon$ 2	H-bond
CDR3 $\beta$ -N	Pro <sup>107</sup>	Gln <sup>7</sup> , Gly <sup>8</sup>	VDW



CDR: complementarity-determining region; FW: framework; V: variable; J: junction; N: non-germline; VDW: van der Waals; H-bond: hydrogen bond.

**Table S4. Contact table for the SB47 TCR with the HLA-B\*35:08<sup>LPEP</sup> complex.**










<b>TCR gene segment</b>	<b>SB47 TCR</b>	<b>HLA-B*35:08</b>	<b>Type of bond</b>
CDR1 $\alpha$	Asp <sup>37</sup>	Trp <sup>167</sup> , Arg <sup>170</sup>	VDW
CDR1 $\alpha$	Asp <sup>37</sup> O- $\delta$ 1, $\delta$ 2	Arg <sup>170</sup> NH1, NH2	Salt bridge
CDR2 $\alpha$	Leu <sup>57</sup>	Leu <sup>163</sup>	VDW
CDR2 $\alpha$	Ser <sup>58</sup>	Gly <sup>162</sup> , Glu <sup>166</sup>	VDW
CDR2 $\alpha$	Asn <sup>59</sup>	Glu <sup>166</sup>	VDW
CDR2 $\alpha$	Asn <sup>59</sup> N	Glu <sup>166</sup> O- $\epsilon$ 1	H-bond
FW $\alpha$	Thr <sup>82</sup>	Glu <sup>166</sup>	VDW
CDR3 $\alpha$ -N	Gly <sup>109</sup>	Glu <sup>55</sup> , Gly <sup>56</sup> , Arg <sup>170</sup>	VDW
CDR3 $\alpha$ -N	Gly <sup>109</sup> O	Gly <sup>56</sup> N	H-bond
CDR3 $\alpha$ -J	Ser <sup>110</sup>	Gly <sup>56</sup> , Pro <sup>57</sup> , Glu <sup>58</sup> , Tyr <sup>59</sup> , Trp <sup>167</sup> , Arg <sup>170</sup>	VDW
CDR3 $\alpha$ -J	Ser <sup>110</sup> O	Glu <sup>58</sup> N	H-bond
CDR3 $\alpha$ -J	Ser <sup>110</sup> O- $\gamma$	Glu <sup>55</sup> O- $\epsilon$ 1	H-bond
CDR3 $\alpha$ -J	Asn <sup>111</sup>	Pro <sup>57</sup> , Glu <sup>58</sup>	VDW
CDR3 $\alpha$ -J	Tyr <sup>112</sup>	Pro <sup>57</sup> , Glu <sup>58</sup> , Asp <sup>61</sup>	VDW
CDR3 $\alpha$ -J	Tyr <sup>112</sup> OH	Asp <sup>61</sup> O- $\delta$ 2	H-bond
CDR2 $\beta$	Tyr <sup>57</sup>	Asp <sup>61</sup> , Gln <sup>65</sup>	VDW
CDR2 $\beta$	Glu <sup>58</sup> O- $\epsilon$ 1	Lys <sup>68</sup> N $\zeta$	Salt bridge
FW $\beta$	Arg <sup>66</sup>	Pro <sup>57</sup> , Asp <sup>61</sup>	VDW
FW $\beta$	Arg <sup>66</sup> N- $\epsilon$	Asp <sup>61</sup> O- $\delta$ 1, $\delta$ 2	H-bond
FW $\beta$	Arg <sup>66</sup> NH2	Pro <sup>57</sup> O	H-bond
FW $\beta$	Arg <sup>66</sup> NH1, NH2	Asp <sup>61</sup> O- $\delta$ 1, $\delta$ 2	Salt bridge
FW $\beta$	Gln <sup>67</sup>	Pro <sup>57</sup>	VDW
CDR3 $\beta$ -N	Thr <sup>109</sup>	Gln <sup>65</sup> , Asp <sup>61</sup>	VDW
CDR3 $\beta$ -N	Gly <sup>110</sup>	Arg <sup>62</sup> , Ile <sup>66</sup>	VDW
CDR3 $\beta$ -N	Gly <sup>110</sup> O	Arg <sup>62</sup> NH1	H-bond
CDR3 $\beta$ -J	Ser <sup>111</sup>	Arg <sup>62</sup>	VDW
CDR3 $\beta$ -J	Ser <sup>111</sup> O	Arg <sup>62</sup> NH1, NH2	H-bond
CDR3 $\beta$ -J	Tyr <sup>113</sup>	Arg <sup>62</sup>	VDW
CDR3 $\beta$ -J	Tyr <sup>113</sup> OH	Arg <sup>62</sup> NH1	H-bond
<b>TCR gene segment</b>	<b>SB47 TCR</b>	<b>LPEP peptide</b>	<b>Type of bond</b>
CDR3 $\beta$ -N	Arg <sup>108</sup>	Leu <sup>5</sup> , Pro <sup>6</sup> , Gln <sup>7</sup>	VDW
CDR3 $\beta$ -N	Arg <sup>108</sup> NH2	Pro <sup>6</sup> O, Gln <sup>7</sup> O, Gly <sup>8</sup> O	H-bond
CDR3 $\beta$ -N	Thr <sup>109</sup>	Leu <sup>5</sup>	VDW
CDR3 $\beta$ -N	Gly <sup>110</sup>	Pro <sup>4</sup> , Leu <sup>5</sup>	VDW
CDR3 $\beta$ -N	Gly <sup>110</sup> O	Leu <sup>5</sup> N	H-bond
CDR3 $\beta$ -J	Ser <sup>111</sup>	Pro <sup>4</sup> , Leu <sup>5</sup> , Pro <sup>6</sup> , Gln <sup>7</sup>	VDW
CDR3 $\beta$ -J	Ser <sup>111</sup> O- $\gamma$	Leu <sup>5</sup> O, Pro <sup>6</sup> O	H-bond
CDR3 $\beta$ -J	Thr <sup>112</sup>	Leu <sup>5</sup> , Gln <sup>7</sup>	VDW
CDR3 $\beta$ -J	Tyr <sup>113</sup>	Leu <sup>1</sup>	VDW
CDR3 $\beta$ -J	Glu <sup>114</sup>	Gln <sup>7</sup>	VDW

CDR: complementarity-determining region; FW: framework; V: variable; J: junction; N: non-germline; VDW: van der Waals; H-bond: hydrogen bond.





Supplementary Figure 1.



Supplementary Figure 2.



Supplementary Figure 3.





Supplementary Figure 4.

